Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States

Prior observational studies suggest rivaroxaban is safe and effective among patients with morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are more limited in the broader population of VTE patients with obesity. This study assessed VTE recurrence, major bleeding, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Jeffrey S., Laliberté, François, Kharat, Akshay, Lejeune, Dominique, Moore, Kenneth Todd, Jung, Young, Lefebvre, Patrick, Ashton, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553828/
https://www.ncbi.nlm.nih.gov/pubmed/35562510
http://dx.doi.org/10.1007/s11239-022-02661-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553828/
https://www.ncbi.nlm.nih.gov/pubmed/35562510
http://dx.doi.org/10.1007/s11239-022-02661-1

Ejemplares similares